Gastrointestinal Safety of Direct Oral Anticoagulants

A Large Population-Based Study

Neena Susan Abraham, Peter Noseworthy, Xiaoxi Yao, Lindsey R. Sangaralingham, Nilay D Shah

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding. Methods We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare Advantage enrollees. We created 3 propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015. We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients. Cox proportional hazards models, stratified by age, were used to estimate rates of total GI bleeding. Results Baseline characteristics were well balanced among sub-cohorts. GI bleeding occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.00−1.45). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95% CI, 0.27−0.58; P <.001) or rivaroxaban (HR, 0.33; 95% CI, 0.22−0.49; P < .001). Rates of events for all DOACs increased among patients 75 years or older. Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29−0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25−0.61). Median times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran. Conclusions In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile. GI bleeding events among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among persons 75 years. Apixaban had the most favorable GI safety profile among all age groups.

Original languageEnglish (US)
Pages (from-to)1014-1022.e1
JournalGastroenterology
Volume152
Issue number5
DOIs
StatePublished - Apr 1 2017

Fingerprint

Anticoagulants
Hemorrhage
Safety
Population
Confidence Intervals
Medicare Part C
apixaban
Rivaroxaban
Dabigatran
Proportional Hazards Models
Atrial Fibrillation
Age Groups
Pharmaceutical Preparations

Keywords

  • Anticoagulant
  • Atrial Fibrillation
  • Comparative Safety
  • Gastrointestinal Hemorrhage

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gastrointestinal Safety of Direct Oral Anticoagulants : A Large Population-Based Study. / Abraham, Neena Susan; Noseworthy, Peter; Yao, Xiaoxi; Sangaralingham, Lindsey R.; Shah, Nilay D.

In: Gastroenterology, Vol. 152, No. 5, 01.04.2017, p. 1014-1022.e1.

Research output: Contribution to journalArticle

@article{63df54e34fac4a19bbb3ae88b67ace37,
title = "Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study",
abstract = "Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding. Methods We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare Advantage enrollees. We created 3 propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015. We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients. Cox proportional hazards models, stratified by age, were used to estimate rates of total GI bleeding. Results Baseline characteristics were well balanced among sub-cohorts. GI bleeding occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95{\%} confidence interval [CI], 1.00−1.45). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95{\%} CI, 0.27−0.58; P <.001) or rivaroxaban (HR, 0.33; 95{\%} CI, 0.22−0.49; P < .001). Rates of events for all DOACs increased among patients 75 years or older. Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95{\%} CI, 0.29−0.71) or rivaroxaban (HR, 0.39; 95{\%} CI, 0.25−0.61). Median times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran. Conclusions In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile. GI bleeding events among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among persons 75 years. Apixaban had the most favorable GI safety profile among all age groups.",
keywords = "Anticoagulant, Atrial Fibrillation, Comparative Safety, Gastrointestinal Hemorrhage",
author = "Abraham, {Neena Susan} and Peter Noseworthy and Xiaoxi Yao and Sangaralingham, {Lindsey R.} and Shah, {Nilay D}",
year = "2017",
month = "4",
day = "1",
doi = "10.1053/j.gastro.2016.12.018",
language = "English (US)",
volume = "152",
pages = "1014--1022.e1",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Gastrointestinal Safety of Direct Oral Anticoagulants

T2 - A Large Population-Based Study

AU - Abraham, Neena Susan

AU - Noseworthy, Peter

AU - Yao, Xiaoxi

AU - Sangaralingham, Lindsey R.

AU - Shah, Nilay D

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding. Methods We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare Advantage enrollees. We created 3 propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015. We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients. Cox proportional hazards models, stratified by age, were used to estimate rates of total GI bleeding. Results Baseline characteristics were well balanced among sub-cohorts. GI bleeding occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.00−1.45). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95% CI, 0.27−0.58; P <.001) or rivaroxaban (HR, 0.33; 95% CI, 0.22−0.49; P < .001). Rates of events for all DOACs increased among patients 75 years or older. Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29−0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25−0.61). Median times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran. Conclusions In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile. GI bleeding events among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among persons 75 years. Apixaban had the most favorable GI safety profile among all age groups.

AB - Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding. Methods We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare Advantage enrollees. We created 3 propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015. We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients. Cox proportional hazards models, stratified by age, were used to estimate rates of total GI bleeding. Results Baseline characteristics were well balanced among sub-cohorts. GI bleeding occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.00−1.45). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95% CI, 0.27−0.58; P <.001) or rivaroxaban (HR, 0.33; 95% CI, 0.22−0.49; P < .001). Rates of events for all DOACs increased among patients 75 years or older. Apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29−0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25−0.61). Median times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran. Conclusions In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile. GI bleeding events among patient aged 75 years or older taking DOACs increased with age; the risk was greatest among persons 75 years. Apixaban had the most favorable GI safety profile among all age groups.

KW - Anticoagulant

KW - Atrial Fibrillation

KW - Comparative Safety

KW - Gastrointestinal Hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85016224393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016224393&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2016.12.018

DO - 10.1053/j.gastro.2016.12.018

M3 - Article

VL - 152

SP - 1014-1022.e1

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -